Sangamo Therapeutics (SGMO)
(Real Time Quote from BATS)
$0.59 USD
+0.02 (2.73%)
Updated Jun 10, 2024 10:50 AM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SGMO 0.59 +0.02(2.73%)
Will SGMO be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGMO
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy
Other News for SGMO
Sangamo Biosciences Positions for Growth with Strategic Shareholder Decisions
Nektar, Verastem among healthcare additions in Russell Microcap; Assertio, Sangamo removed
Russell 3000: Inovio, Ocugen among healthcare additions; Assertio, Ginkgo Bioworks among deletions
Commit To Purchase Sangamo Therapeutics At $0.50, Earn 59.8% Annualized Using Options
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know